Related Experiment Video
Updated: Jul 2, 2025
Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies
Published on: September 15, 2023
A Comprehensive Prognostic and Immune Infiltration Analysis of RBM4 in Pan-Cancer
Jia-Jun Ding1, Jie Wu2, Hai-Lei Bian1
1Department of Operating Room, Shanghai East Hospital, School of Medicine, Tongji University, 200120 Shanghai, China.
Background:
Aberrant splicing has been closely associated with human cancer, though the precise underlying mechanisms linking the two remain not fully understood. Investigating the role of splicing factors in cancer progression may aid in the development of targeted therapies for dysregulated splicing, thereby opening up new avenues for cancer treatment. RNA-binding motif 4 (RBM4) has been identified as a critical participant in the condensin II complex, which is involved in chromosome condensation and stabilization during mitosis. Its significance in tumors is currently gaining attention. The genetic characteristics of RBM4 suggest its potential to elucidate the malignant progression of tumors in a broader context, encompassing various types of cancer, known as pan-cancer.
Methods:
This study aims to comprehensively explore the potential function of RBM4 in pan-cancer by leveraging existing databases such as The Cancer Genome Atlas (TCGA) and Genotype-Tissue Expression (GTEx).
Results:
RBM4 is found to be overexpressed in almost all tumors and exhibits significant prognostic and diagnostic efficacy. The correlation between RBM4 and immune signatures, including immune cell infiltration and immune checkpoint genes, indicates that RBM4 could serve as a guiding factor for immunotherapy.
Conclusions:
As a member of the pan-oncogene, RBM4 has the potential to become a biomarker and therapeutic target for various malignant tumors, offering novel possibilities for precision medicine.
Insights
RNA-binding motif 4 (RBM4) is overexpressed in most cancers and shows promise as a pan-cancer biomarker. Its correlation with immune signatures suggests RBM4 could guide immunotherapy strategies for various malignant tumors.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Genomics
Background:
- Aberrant RNA splicing is linked to human cancers, but mechanisms are unclear.
- Splicing factors like RNA-binding motif 4 (RBM4) are crucial for chromosome stability and are gaining attention in tumor research.
- RBM4's role in pan-cancer progression warrants investigation for targeted therapies.
Purpose of the Study:
- To comprehensively explore the pan-cancer function of RBM4.
- To investigate RBM4's potential as a biomarker and therapeutic target.
Main Methods:
- Utilized The Cancer Genome Atlas (TCGA) and Genotype-Tissue Expression (GTEx) databases.
- Analyzed RBM4 expression patterns across various cancer types.
- Correlated RBM4 with prognostic, diagnostic, and immune signatures.
Main Results:
- RBM4 is overexpressed in nearly all analyzed tumors.
- RBM4 demonstrates significant prognostic and diagnostic value.
- RBM4 expression correlates with immune cell infiltration and immune checkpoint genes, suggesting its role in immunotherapy.
Conclusions:
- RBM4 functions as a pan-oncogene with potential as a biomarker and therapeutic target for diverse malignancies.
- RBM4 offers new possibilities for precision medicine in cancer treatment.
